LON:AGY - Allergy Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 14.23 -0.03 (-0.21 %)
(As of 02/21/2019 07:11 AM ET)
Previous CloseGBX 14.25
Today's RangeGBX 14.14 - GBX 14.25
52-Week RangeGBX 23 - GBX 39.50
Volume29,511 shs
Average Volume167,682 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil. It also develops clinical pipeline products that include vaccines for grass, tree, and house dust mite, as well as a peanut allergy vaccine that is in pre-clinical stage. The company primarily sells its products in European countries. Allergy Therapeutics plc was founded in 1934 and is based in Worthing, the United Kingdom.

Receive AGY News and Ratings via Email

Sign-up to receive the latest news and ratings for AGY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone+44-1903-844700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees499
OptionableNot Optionable

Allergy Therapeutics (LON:AGY) Frequently Asked Questions

What is Allergy Therapeutics' stock symbol?

Allergy Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "AGY."

What price target have analysts set for AGY?

1 brokers have issued 12 month price objectives for Allergy Therapeutics' stock. Their predictions range from GBX 45 to GBX 47. On average, they anticipate Allergy Therapeutics' stock price to reach GBX 46 in the next twelve months. This suggests a possible upside of 223.4% from the stock's current price. View Analyst Price Targets for Allergy Therapeutics.

What is the consensus analysts' recommendation for Allergy Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allergy Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allergy Therapeutics.

Has Allergy Therapeutics been receiving favorable news coverage?

Press coverage about AGY stock has been trending positive this week, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Allergy Therapeutics earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an impact on the company's share price in the immediate future.

Who are some of Allergy Therapeutics' key competitors?

Who are Allergy Therapeutics' key executives?

Allergy Therapeutics' management team includes the folowing people:
  • Mr. Manuel Llobet, CEO & Exec. Director (Age 55)
  • Mr. Nicolas Alexander Ulrich Wykeman, CFO & Director (Age 54)
  • Ms. Beverly Lees, Group Operations Director
  • Dr. Murray Skinner, Chief Scientific Officer
  • Mr. Santiago Puig, Bus. Devel. Director

How do I buy shares of Allergy Therapeutics?

Shares of AGY and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Allergy Therapeutics' stock price today?

One share of AGY stock can currently be purchased for approximately GBX 14.23.

What is Allergy Therapeutics' official website?

The official website for Allergy Therapeutics is http://www.allergytherapeutics.com/.

How can I contact Allergy Therapeutics?

Allergy Therapeutics' mailing address is Dominion Way, WORTHING, BN14 8SA, United Kingdom. The company can be reached via phone at +44-1903-844700.


MarketBeat Community Rating for Allergy Therapeutics (LON AGY)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  141 (Vote Underperform)
Total Votes:  439
MarketBeat's community ratings are surveys of what our community members think about Allergy Therapeutics and other stocks. Vote "Outperform" if you believe AGY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Featured Article: Moving Average (MA)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel